Search review questions

Reoperation rate ‐ not reported · children younger than two years of age with bilateral congenital cataracts

Failure to stabilise optic neuropathy progression (as defined by study investigators) · people with open‐angle glaucoma

Quality of life · people with open‐angle glaucoma

Improvement in central macular thickness on OCT · participants with chronic CME (≥ 4 months) following cataract surgery

Improved contrast sensitivity · participants with chronic CME (≥ 4 months) following cataract surgery

Change in QoL · participants with chronic CME (≥ 4 months) following cataract surgery

Persistence of visual improvement one month after discontinuation of treatment · participants with acute or chronic CME following cataract surgery

Improvement in leakage on FFA · participants with acute or chronic CME following cataract surgery

Improvement in central macular thickness on OCT · participants with acute or chronic CME following cataract surgery

Improved contrast sensitivity · participants with acute or chronic CME following cataract surgery

Change in QoL · participants with acute or chronic CME following cataract surgery

Persistence of visual improvement one month after discontinuation of treatment · participants with acute CME (< 4 months) following cataract surgery

Improvement in central macular thickness on OCT · participants with acute CME (< 4 months) following cataract surgery

Change in QoL · participants with acute CME (< 4 months) following cataract surgery

Change in distance BCVA in the amblyopic eye 12 months after cessation of treatment · 5‐ to 8‐year‐old children with amblyopia

Change in the interocular difference in contrast sensitivity Any validated test, from baseline to 16 (± 2) weeks · 5‐ to 8‐year‐old children with amblyopia

Measurable change in stereopsis after 8 (± 2) weeks and 16 (± 2) weeks of intervention 'Real change' in stereopsis is defined as a change in stereoacuity of two or more octaves. · 5‐ to 8‐year‐old children with amblyopia

Outcomes* · eyes with acute endophthalmitis following an intraocular procedure (e.g. surgery, intravitreous injection)

Improvement in visual acuity at 3 months' · eyes with acute endophthalmitis following an intraocular procedure (e.g. surgery, intravitreous injection)

Costs associated with the interventions at 3 months' · eyes with acute endophthalmitis following an intraocular procedure (e.g. surgery, intravitreous injection)

Total costs per QALY · people with bilateral age‐related cataracts (NRSs)

BCDVA · people with bilateral age‐related cataracts (NRSs)

PROM · people with bilateral age‐related cataracts (NRSs)

Total costs per QALY · people with bilateral age‐related cataracts (RCTs)

Proportion of all‐cause mortality at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Mean time to first relapse after induction of remission (weeks) at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Proportion of all‐cause mortality at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Mean time to first relapse after induction of remission (weeks) at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Proportion of all‐cause mortality at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Mean time to first relapse after induction of remission (weeks) at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Proportion of all‐cause mortality at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Mean time to first relapse after induction of remission (weeks) at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Proportion of participants who did not need escape therapy (as defined by study investigators) · adults aged over 50 years with giant cell arteritis

Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey physical component score (SF‐36 PCS) · adults aged over 50 years with giant cell arteritis

Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) · adults aged over 50 years with giant cell arteritis

Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Proportion of initially unaffected fellow eyes that had signs/symptoms of infection within 7 days of onset of signs/symptoms in the first eye (lower is favored) · epidemic keratoconjunctivitis

Proportion of participants with resolution of signs within 7 days of treatment (higher is favored) · epidemic keratoconjunctivitis

Proportion of participants in whose eyes SEI had disappeared within 21 days of treatment initiation (higher is favored) · epidemic keratoconjunctivitis

Proportion of participants who discontinued medication and did not develop rebound SEI within 21 days (higher is favored) · epidemic keratoconjunctivitis

Proportion of initially unaffected fellow eyes that had signs/symptoms of infection within 7 days of onset of signs/symptoms in the first eye (lower is favored) · epidemic keratoconjunctivitis

Proportion of participants who discontinued medication and did not develop rebound SEI within 21 days (higher is favored) · epidemic keratoconjunctivitis

Proportion of initially unaffected fellow eyes that had signs/symptoms of infection within 7 days of onset of signs/symptoms in the first eye (lower is favored) · epidemic keratoconjunctivitis

Mean change in best‐corrected visual acuity · people with endophthalmitis following intraocular surgery

Quality of life. · people with endophthalmitis following intraocular surgery

Glaucoma progression at 12 months, measured by additional visual field defects · people with primary open‐angle glaucoma or ocular hypertension